Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 1;33(Suppl 1):S-70–S-80. doi: 10.1089/aid.2017.0159

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2017, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 3. — Lymphopenia and reduction of CCR5⁺ populations in blood after CCR5xCD3 bispecific antibody treatment. (A) Flow cytometry of whole blood from 1.5-year-old rhesus macaques treated with 1 mg/kg bispecific antibody, gated on forward/side scatter, single cells, and live/dead only. Blood was taken before treatment, 4 h after treatment, and 1 week after treatment. (B, C) Representative cytograms (B) and longitudinal plots (C) of CD3⁺ lymphocytes from rhesus macaques receiving 1 mg/kg at pretreatment, 4 h, 1 week, and 3 weeks from drug administration. (D) Flow cytometry of whole blood from 1.5-year-old rhesus macaques treated with 3 mg/kg bispecific antibody. (E, F) Representative cytograms (E) and longitudinal plots (F) of CD3⁺ lymphocytes from rhesus macaques receiving 3 mg/kg. (G) Whole blood staining of 8-month-old rhesus macaques treated with 3 mg/kg of bispecific antibody, demonstrating loss of CD3⁺ cells from blood.